Chinese pharmaceutical start-up Ascletis has completed RMB220 million (US$35 million) new round of financing led by C-Bridge Capital, according to a company announcement. Chinese drug maker Tasly Pharmaceutical and Singapore-based Pavilion Capital also participated in the round, which values the company at US$300 million before the round’s completion. The proceeds from this financing will be […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.